Education
About Us
Working with TipRanks
Follow Us
Bio-Rad Laboratories (CH:BUWA)
:BUWA
Total Valuation
Bio-Rad Laboratories has a market cap or net worth of ―. The enterprise value is ―.
Market Cap―
Enterprise Value―
Share Statistics
Bio-Rad Laboratories has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bio-Rad Laboratories’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is 2.37%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)2.37%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee333.31K
Profits Per Employee-239.51K
Employee Count7,700
Asset Turnover0.27
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bio-Rad Laboratories is -5.03. Bio-Rad Laboratories’s PEG ratio is 0.18.
PE Ratio-5.03
PS Ratio―
PB Ratio1.00
Price to Fair Value1.41
Price to FCF19.72
Price to Operating Cash Flow13.02
PEG Ratio0.18
Income Statement
In the last 12 months, Bio-Rad Laboratories had revenue of 2.57B and earned -1.84B in profits. Earnings per share was -65.36.
Revenue2.57B
Gross Profit1.38B
Operating Income269.00M
Pretax Income-2.34B
Net Income-1.84B
EBITDA-2.10B
Earnings Per Share (EPS)-65.36
Cash Flow
In the last 12 months, operating cash flow was 515.31M and capital expenditures -183.22M, giving a free cash flow of 332.08M billion.
Operating Cash Flow515.31M
Free Cash Flow332.08M
Free Cash Flow per Share―
Dividends & Yields
Bio-Rad Laboratories pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Bio-Rad Laboratories upcoming earnings date is Jul 24, 2025, TBA Not Confirmed.
Last Earnings DateMay 1, 2025
Next Earnings DateJul 24, 2025
Ex-Dividend Date―
Financial Position
Bio-Rad Laboratories as a current ratio of 6.48, with Debt / Equity ratio of 20.50%
Current Ratio6.48
Quick Ratio6.48
Debt to Market Cap0.13
Net Debt to EBITDA-0.42
Interest Coverage Ratio5.50
Taxes
In the past 12 months, Bio-Rad Laboratories has paid -498.30M in taxes.
Income Tax-498.30M
Effective Tax Rate0.21
Enterprise Valuation
Bio-Rad Laboratories EV to EBITDA ratio is -4.83, with an EV/FCF ratio of 38.15.
EV to Sales3.96
EV to EBITDA-4.83
EV to Free Cash Flow38.15
EV to Operating Cash Flow22.31
Balance Sheet
Bio-Rad Laboratories has $1.66M in cash and marketable securities with $1.37B in debt, giving a net cash position of $1.37B billion.
Cash & Marketable Securities$1.66M
Total Debt$1.37B
Net Cash$1.37B
Net Cash Per Share―
Tangible Book Value Per Share$207.88
Margins
Gross margin is 53.50%, with operating margin of 10.48%, and net profit margin of -71.86%.
Gross Margin53.50%
Operating Margin10.48%
Pretax Margin-91.27%
Net Profit Margin-71.86%
EBITDA Margin-81.85%
EBIT Margin-89.37%
Analyst Forecast
The average price target for Bio-Rad Laboratories is $263.66, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$263.66
Price Target Upside― Downside
Analyst ConsensusModerate Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast―